Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL447074 | 0.97 | CA4 (0.90) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL18797951 | 0.97 | CA4 (0.80) | CA4ALDH1A1 | |
| Citric Acid SCHEMBL29775 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL17240265 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL8845344 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL28166882 | 0.95 | CA4 (0.76) | CA4 | |
| Citric Acid SCHEMBL372478 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL8066143 | 0.94 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL6055779 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL1065771 | 0.94 | CA4 (0.94) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250197-A1 | AN INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2016-09-01 | — | — | US | claimed |
| US-9644131-B2 | Alternative ligand formulations for cellulose products | CP KELCO OY (FI) | 2017-05-09 | — | — | US | disclosed |
| EP-2751216-A1 | \"ALTERNATIVE LIGAND FORMULATIONS FOR CELLULOSE PRODUCTS\ | CP Kelco Oy (FI) | 2014-07-09 | — | — | EP | disclosed |
| CN-102210370-B | Low-sugar pawpaw preserved fruit and preparation method thereof | GUANGDONG SHENGBAO PLANTING & BREEDING CO LTD | 2013-04-17 | — | — | CN | disclosed |
| WO-2013029864-A1 | \"ALTERNATIVE LIGAND FORMULATIONS FOR CELLULOSE PRODUCTS\ | CP KELCO OY (FI) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053283-A1 | ALTERNATIVE LIGAND FORMULATIONS FOR CELLULOSE PRODUCTS | CP KELCO OY (FI) | 2013-02-28 | — | — | US | disclosed |
| CN-102210370-A | Low-sugar pawpaw preserved fruit and preparation method thereof | GUANGDONG SHENGBAO PLANTING & BREEDING CO LTD | 2011-10-12 | — | — | CN | disclosed |
| EP-0625894-A1 | AQUEOUS GEL WOUND DRESSING AND PACKAGE | LecTec Corporation (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0625894-A4 | AQUEOUS GEL WOUND DRESSING AND PACKAGE. | LECTEC CORPORATION (US) | 1994-09-01 | — | — | EP | disclosed |
| WO-1993006802-A1 | AQUEOUS GEL WOUND DRESSING AND PACKAGE | ROLF DAVID (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250197-A1 | AN INHALABLE MEDICAMENT | ORAI1, CA2, TRPM8 | CA4 171/4885ALDH1A1 3967/4885CASP1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.